RxDoctor Payments Data

Shayla Jefferson

Psychiatric/Mental Health · Milwaukee, WINPI 1669926564

Payments from drug & device makers

$1,819in general payments, 2019–2025

Across 71 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$557
  • AbbVie$377
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$281
  • Lundbeck LLC$175
  • Exact Sciences$75
  • Pfizer$51
  • plus $303 from 15 others

What the payments were for

  • Food & beverage$1,819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,819 in reported general payments places this provider in the 75th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$2,899
Medicare patients
23
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$29,408
VraylarCariprazine Hcl19$27,214
EliquisApixaban23$6,659
Buspirone Hcl44$1,657
Sertraline Hcl60$789
Hydroxyzine Hcl36$698
Divalproex Sodium19$589
Mirtazapine35$538
Escitalopram Oxalate48$509
Oxybutynin Chloride ErOxybutynin Chloride12$375
Quetiapine Fumarate24$334
Aripiprazole18$330
Olanzapine17$328
Benztropine Mesylate15$237
Omeprazole13$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$377$27,21419 claims
PfizerEliquis$51$6,65923 claims
Lilly USA, LLCOlanzapine$20$32817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →